☰

Sarah K. Knutson, Ph.D. - Publications

Affiliations: 
2008 Vanderbilt University, Nashville, TN 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ, Copeland RA, Keilhack H, Chan-Penebre E, Knutson SK, Ribich SA, Raimondi A, et al. EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL. Molecular Cancer Therapeutics. PMID 28835384 DOI: 10.1158/1535-7163.Mct-16-0840  0.435
2017 Chan-Penebre E, Armstrong K, Drew A, Grassian AR, Feldman I, Knutson SK, Kuplast-Barr K, Roche M, Campbell J, Ho P, Copeland RA, Chesworth R, Smith JJ, Keilhack H, Ribich SA. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: In vitro and in vivo preclinical models. Molecular Cancer Therapeutics. PMID 28292935 DOI: 10.1158/1535-7163.Mct-16-0678  0.479
2016 Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JS, Kuntz KK, Ribich S, Minoshima Y, Matsui J, Copeland RA, et al. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. Plos One. 11: e0158888. PMID 27391784 DOI: 10.1371/Journal.Pone.0158888  0.502
2016 LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, et al. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine. 22: 578-579. PMID 27270773 DOI: 10.1038/Nm.4094  0.311
2016 Kuntz KW, Campbell JE, Keilhack H, Pollock RM, Knutson SK, Porter Scott M, Richon VM, Sneeringer CJ, Wigle TJ, Allain CJ, Majer CR, Moyer MP, Copeland RA, Chesworth R. The importance of being Me: Magic methyls, methyltransferase inhibitors and the discovery of tazemetostat. Journal of Medicinal Chemistry. PMID 26769278 DOI: 10.1021/Acs.Jmedchem.5B01501  0.437
2015 Grassian AR, Scales TM, Knutson SK, Kuntz KW, McCarthy NJ, Lowe CE, Moore JD, Copeland RA, Keilhack H, Smith JJ, Wickenden JA, Ribich S. A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality. Biological Procedures Online. 17: 15. PMID 26578851 DOI: 10.1186/S12575-015-0028-4  0.397
2015 LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine. PMID 26437366 DOI: 10.1038/Nm.3947  0.501
2015 Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, Raimondi A, Klaus CR, Rioux N, Yokoi A, Kawano S, Minoshima Y, Choi HW, Porter Scott M, Waters NJ, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. Acs Medicinal Chemistry Letters. 6: 491-5. PMID 26005520 DOI: 10.1021/Acsmedchemlett.5B00037  0.387
2015 LaFave LM, Béguelin W, Koche R, Teater M, Papalexi E, Spitzer B, Knutson S, Campbell J, Keilhack H, Thomas PM, Kelleher NL, Abdel-Wahab O, Melnick AM, Armstrong SA, Levine RL. BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes Blood. 126: 713-713. DOI: 10.1182/Blood.V126.23.713.713  0.451
2015 Knutson SK, Drew AE, Plescia C, Copeland RA, Smith JJ, Keilhack H, Ribich S. Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C87  0.464
2015 Grassian AR, Scales T, Knutson SK, McCarthy NJ, Lowe CE, Moore JD, Copeland RA, Keilhack H, Smith JJ, Wickendon JA, Ribich S. Abstract C162: A medium-throughput single cell CRISPR-Cas9 assay to assess gene essentiality Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C162  0.383
2015 Johnston D, Brach D, Plescia C, Drew A, Lingaraj T, Warholic N, Smith JJ, Copeland RA, Keilhack H, Penebre E, Knutson SK, Ribich S, Thomenius MJ, Raimondi A. Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B85  0.39
2015 Plescia C, Knutson S, Warholic N, McDonald A, Keilhack H, Smith J, Copeland R, Blakemore S. Abstract B133: Chromatin flow cytometry based quantification of cell type specific alterations in histone methylation states resulting from in vitro and in vivo EZH2 inhibitor treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B133  0.492
2014 Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Porter-Scott M, Smith JJ, Moyer MP, Copeland RA, Pollock RM, Kuntz KW, Raimondi A, Keilhack H. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. Plos One. 9: e111840. PMID 25493630 DOI: 10.1371/Journal.Pone.0111840  0.455
2014 Swalm BM, Knutson SK, Warholic NM, Jin L, Kuntz KW, Keilhack H, Smith JJ, Pollock RM, Moyer MP, Scott MP, Copeland RA, Wigle TJ. Reaction coupling between wild-type and disease-associated mutant EZH2. Acs Chemical Biology. 9: 2459-64. PMID 25154026 DOI: 10.1021/Cb500548B  0.405
2014 Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molecular Cancer Therapeutics. 13: 842-54. PMID 24563539 DOI: 10.1158/1535-7163.Mct-13-0773  0.487
2013 Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Scott MP, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM, Kuntz KW, Keilhack H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proceedings of the National Academy of Sciences of the United States of America. 110: 7922-7927. PMID 23620515 DOI: 10.1073/Pnas.1303800110  0.423
2013 Johnston LD, Knutson S, Warholic N, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Scott MP, Smith JJ, Moyer MP, Copeland RA, Pollock RM, Kuntz KW, Keilhack H, Raimondi A. EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models Blood. 122: 4416-4416. DOI: 10.1182/Blood.V122.21.4416.4416  0.415
2012 Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology. 8: 890-6. PMID 23023262 DOI: 10.1038/Nchembio.1084  0.503
2012 Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, Smith JJ, Moyer MP, Richon VM, Copeland RA, Wigle TJ. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. Febs Letters. 586: 3448-51. PMID 22850114 DOI: 10.1016/J.Febslet.2012.07.066  0.301
2012 Keilhack H, Yokoi A, Knutson SK, Wigle T, Warholic N, Kawano S, Minoshima Y, Huang K, Kuznetsov G, Kumar N, Klaus CR, Allain CJ, Raimondi A, Scott MP, Chesworth R, et al. Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice Blood. 120: 3712-3712. DOI: 10.1182/Blood.V120.21.3712.3712  0.449
2011 Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, Copeland RA, Scott MP. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. Febs Letters. 585: 3011-4. PMID 21856302 DOI: 10.1016/J.Febslet.2011.08.018  0.404
2010 Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 107: 20980-5. PMID 21078963 DOI: 10.1073/Pnas.1012525107  0.464
2010 Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, Washington MK, Zhao Z, Wagner FF, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 18: 436-47. PMID 21075309 DOI: 10.1016/J.Ccr.2010.10.022  0.578
2010 Razidlo DF, Whitney TJ, Casper ME, McGee-Lawrence ME, Stensgard BA, Li X, Secreto FJ, Knutson SK, Hiebert SW, Westendorf JJ. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. Plos One. 5: e11492. PMID 20628553 DOI: 10.1371/Journal.Pone.0011492  0.521
2010 Richon VM, Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Copeland RA. Lymphoma-Associated Mutations of EZH2 Result In a Change-of-Function Blood. 116: 707-707. DOI: 10.1182/Blood.V116.21.707.707  0.434
2008 Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell. 30: 61-72. PMID 18406327 DOI: 10.1016/J.Molcel.2008.02.030  0.589
2008 Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. The Embo Journal. 27: 1017-28. PMID 18354499 DOI: 10.1038/Emboj.2008.51  0.566
Show low-probability matches.